Cholesterol fears rock Immunovant
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
J&J snags novel autoimmune project, and Momenta
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Argenx sets a high bar with a novel drug class
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
